New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
11:29 EDTLH, BRLI, DGXFDA announces steps to ensure reliable diagnostic test results
The FDA announced that it took "important steps to ensure that certain tests used by health care professionals to help diagnose and treat patients provide accurate, consistent and reliable results." The FDA issued a final guidance on the development, review and approval of companion diagnostics, which are tests used to identify patients who will benefit from or be harmed by treatment with a certain drug. Companion diagnostic tests are intended to aid physicians in selecting appropriate therapies for individual patients, the agency said. These tests are commonly used to detect certain types of gene-based cancers. The FDA also is notifying Congress of its intention to publish a proposed risk-based oversight framework for laboratory developed tests, which are designed, manufactured and used within a single laboratory. The agency also intends to publish a draft guidance outlining how laboratories can notify the FDA that they are currently manufacturing and using LDTs, how to provide information about their LDTs, and how they can comply with the medical device reporting requirements. Publicly traded laboratory companies include LabCorp (LH), Quest Diagnostics (DGX) and Bio-Reference Labs (BRLI). Reference Link
News For LH;DGX;BRLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
14:22 EDTLHLabCorp price target raised to $130 from $113 at Craig-Hallum
Subscribe for More Information
November 21, 2014
08:48 EDTLHLabCorp completes acquisition of LipoScience
Subscribe for More Information
November 20, 2014
09:32 EDTLHLipoScience to host special shareholder meeting
Subscribe for More Information
November 19, 2014
10:21 EDTDGXHigh option volume stocks
Subscribe for More Information
November 17, 2014
07:16 EDTDGXMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
07:14 EDTDGXAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
10:01 EDTLHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Hold from Buy at Argus... Adeptus Health (ADPT) downgraded to Hold from Buy at Deutsche Bank... American Woodmark (AMWD) downgraded to Neutral from Buy at Longbow... Avnet (AVT) downgraded to Sell from Neutral at Goldman... Baxano Surgical (BAXS) downgraded to Sell from Buy at Summer Street... Beazer Homes (BZH) downgraded to Neutral from Overweight at JPMorgan... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley... Centene (CNC) downgraded to Market Perform from Outperform at FBR Capital... Cherry Hill Mortgage (CHMI) downgraded to Equal Weight from Overweight at Barclays... Discover (DFS) downgraded to Hold from Buy at Deutsche Bank... Fleetmatics (FLTX) downgraded to Neutral from Buy at BofA/Merrill... Gazprom (OGZPY) downgraded to Neutral from Overweight at JPMorgan... Jabil Circuit (JBL) downgraded to Neutral from Buy at Goldman... LabCorp (LH) downgraded to Hold from Buy at Deutsche Bank... Laredo Petroleum (LPI) downgraded at BMO Capital... Macy's (M) downgraded to Market Perform from Outperform at Wells Fargo... Madison Square Garden (MSG) downgraded to Equal Weight from Overweight at Morgan Stanley... Marvell (MRVL) downgraded to Sell from Neutral at Goldman... Meritor (MTOR) downgraded to Neutral from Overweight at Piper Jaffray... Swedbank (SWDBY) downgraded to Underperform from Sector Perform at RBC Capital... TransGlobe (TGA) downgraded to Sector Perform from Outperform at Scotia Capital... UIL Holdings (UIL) downgraded to Hold from Buy at Argus... Verint Systems (VRNT) downgraded to Fair Value from Buy at CRT Capital... ZAIS Financial (ZFC) downgraded to Equal Weight from Overweight at Barclays.
10:01 EDTDGXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:16 EDTDGX, LHLabCorp downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded LabCorp (LH) to Hold saying revenue synergies from the Covance (CVD) acquisition are "hard to envision." The firm believes LabCorp is now less of a pure play in the Clinical Labs space and lowered its price target for shares to $115 from $120. Deutsche coupled the downgrade with an upgrade of peer Quest (DGX).
06:13 EDTLH, DGXQuest Diagnostics upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use